ZURICH (Reuters) - Swiss pharmaceutical group Novartis said the European Commission has approved its eyecare unit Alcon's Simbrinza treatment for glaucoma, a chronic, sight-threatening eye disease. Alcon said in a statement on Monday the Simbrinza eye drops suspension had been approved to decrease elevated intraocular pressure in adult patients with open-angle glaucoma or ocular hypertension. ...
via Health News Headlines - Yahoo News Read More Here..
No comments:
Post a Comment